ARF1 and prostate carcinoma: We demonstrate here that the combination of Exo2 and salirasib exhibits a superior anticancer activity in prostate cancer, which is mediated at least in part by suppression of tumor growth through co-inhibition of Arf1- and Ras-mediated MAPK activity in cancer cells (Fig. 6).